本次ELCC会议上公布的AMG757是安进公司基于其BiTE双抗技术开发的一种靶向DLL3和CD3且延长半衰期的双特异性抗体,DLL3蛋白在小细胞肺癌肿瘤表面过度表达,在正常组织中低表达,这种差异性使得DLL3成为治疗小细胞肺癌大的一个极有潜力的干预靶点。AMG 757与内源性T细胞和小细胞肺癌细胞结合,诱导T细胞增殖和连续裂解,随后肿...
AMG 757 is being evaluated in a phase 1 clinical trial in patients with relapsed/refractory SCLC (NCT03319940). We evaluated the efficacy and pharmacodynamic (PD) effects of AMG 757 in three preclinical models of SCLC that express DLL3. We used the LXFS 1129 patient-derived xenograft (PDX) ...
November 12, 2020 - AMG 757, a DLL3-directed, half-life extended bispecific T-cell engager (BiTE), was shown to have a feasible adverse effect (AE) profile in patients with small cell lung cancer (SCLC), according to interim results from a phase 1 clinical trial (NCT03319940...